FDA 'POPE' blessing draws Ampio investor praise
This article was originally published in Scrip
Executive Summary
While the announcement on 11 March from Ampio Pharmaceuticals didn't come via white smoke, word that the US FDA had blessed the Colorado biotech's POPE – Patient Outcome for Premature Ejaculation – questionnaire drew praise from investors, with shares jumping 9%.